Mitizodone Phosphate

Mitizodone phosphate is a Chinese-developed small molecule from Sunshine Lake Pharma in Phase 2 testing for major depressive disorder (MDD), with NCT04984512 enrolling 600 patients in an adaptive Phase 2/3 design comparing three doses (10, 20, 40 mg once daily orally) against placebo over a 10-week dosing period [1]. The primary endpoint is change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS, a clinician-administered 10-item depression severity scale) at week 8, the standard yardstick used by FDA, EMA, and China's NMPA (National Medical Products Administration, China's drug regulator) for antidepressant registration [1]. The mechanism of action has not been disclosed in peer-reviewed literature, regulatory filings, or company communications accessible outside China, which makes independent scientific assessment partial. Sunshine Lake Pharma is a subsidiary of HEC Pharm, a privately held Chinese pharmaceutical group whose commercial footprint is concentrated in China and whose international psychiatry track record is thin. The asset has received no FDA breakthrough, fast track, or orphan designations. The most likely near-term outcome is NMPA approval for the Chinese domestic market, where the MDD opportunity is large in patient numbers but compressed in per-patient revenue versus US/EU branded antidepressant economics. For investors and BD teams (business development, the corporate function that negotiates licensing and partnership deals), ex-China value would likely require an out-licensing partner. The pre-computed probability-of-success score sits at 16.7 percent. As discussed in the probability section, this number is best compared against the Phase 2 to Phase 3 transition rate (roughly 40 to 50 percent for CNS programs in Wong et al.), not the end-to-end Phase 2 to approval rate (roughly 6 to 10 percent for psychiatry), and the score sits well below the transition benchmark mainly because the target-novelty penalty is being applied without verified mechanism data [2].

Novel compound, never approved in any market for any indication. The trial is in Phase 2 recruitment as of mid-2026, structured as an adaptive Phase 2/3 design where the dose-finding portion can transition directly into the confirmatory expansion without a hard pause between phases [1]. No FDA breakthrough, fast track, orphan, or RMAT designations have been granted, which is consistent with a program that has not engaged FDA on a pre-IND meeting (the early consultation between sponsor and FDA before filing an Investigational New Drug application, the regulatory submission that authorizes US human testing). Sunshine Lake Pharma is privately held under HEC Pharm, so there are no SEC filings, no quarterly investor updates, and no analyst coverage to mine for timeline guidance. Trial sites appear to be limited to mainland China based on the Dongguan-based sponsor footprint and registry metadata; a parallel ChiCTR (Chinese Clinical Trial Registry) entry is likely but has not been surfaced in indexed sources, and the absence of US or EU sites is itself a signal that FDA-pathway feasibility would require a separate bridging program. No expected primary completion date has been published; the 600-patient enrollment plus 10-week dosing plus safety follow-up plus adaptive transition machinery suggests Phase 2 readout is likely 12 to 24 months out from full enrollment, but this is back-of-envelope rather than guided. There is no published Phase 1 safety paper, no mechanism-of-action publication, and no presentation at a major international psychiatry meeting (ECNP, ASCP, APA) that has surfaced in indexed sources. Chemical identity is fixed through NLM (National Library of Medicine) authoritative identifiers: RxNorm CUI 486961 (RxNorm Concept Unique Identifier, NLM's normalized clinical drug concept code) and UNII NK08V8K8HR (Unique Ingredient Identifier, the FDA's substance-level code). So the molecule itself is real and registered; what is missing is the science around it.

The pharmacological target of mitizodone has not been disclosed in any source accessible outside China. The chemical identity is settled through NLM identifiers (RxNorm CUI 486961, UNII NK08V8K8HR), but the receptor, transporter, or enzyme that the molecule binds has not appeared in peer-reviewed literature, English-language patent abstracts, or regulatory disclosures. One soft inference is available from the WHO INN (International Nonproprietary Name, the globally unique generic name assigned to a drug substance) stem. The 'zodone' suffix is shared with trazodone, a marketed serotonin antagonist and reuptake inhibitor (SARI class) used for depression and insomnia. By INN stem convention, that pattern suggests mitizodone may also act on serotonergic targets, potentially via antagonism at one or more serotonin receptors combined with serotonin reuptake blockade. This is pattern-matching from a naming convention, not confirmed mechanism, and should not be treated as evidence until Sunshine Lake or HEC Pharm publishes a target or files a patent that lands in English-language indexes. Without that confirmation, the strength of the biological rationale cannot be evaluated externally. MDD itself is a well-validated commercial indication where multiple mechanisms have produced approvals: monoamine modulators (the SSRI class, the Prozac family of drugs that block reabsorption of the mood neurotransmitter serotonin, and the SNRI class such as Cymbalta that block both serotonin and norepinephrine reuptake), an NMDA receptor antagonist (esketamine, marketed as Spravato) [3], and a GABA-A receptor positive allosteric modulator (zuranolone, marketed as Zurzuvae) [4]. The bar for a new entrant is no longer placebo separation alone. It is differentiation on speed of onset, durability of response, or tolerability against a category dominated by cheap generic SSRIs. Until Sunshine Lake publishes mechanism data or files a patent that surfaces in international indexes, mitizodone remains a black box from a science-due-diligence standpoint.

NCT04984512 enrolls 600 adults with MDD into an adaptive Phase 2/3 design [1]. Registry metadata confirms a multicenter, randomized, double-blind, parallel-group, placebo-controlled structure with three active-dose arms (10 mg, 20 mg, 40 mg orally once daily) against placebo, dosed for 10 weeks, with the primary endpoint of change from baseline in MADRS total score at week 8 [1]. This is the conventional endpoint and timepoint accepted by FDA, EMA, and NMPA for antidepressant registration, so the regulatory framing is unobjectionable. The 600-patient size is generous for Phase 2 dose-finding and suggests the sponsor intends to seed the Phase 3 confirmatory expansion from the same cohort, a common pattern in adaptive designs that compresses development time when the dose-response data are clean. The trial is recruiting as of the most recent ClinicalTrials.gov refresh [1]. Several design specifics are not visible in the public record: whether an active comparator arm (such as escitalopram, the most common active reference in modern MDD trials) is also included alongside placebo, the randomization ratio across the four (or potentially five) arms, the pre-specified adaptation rules for dose selection and Phase 3 transition, and whether interim futility analyses are built in. Without those details, trial-quality assessment is partial. MADRS at week 8 is unforgiving in this indication; MDD trials run by sponsors with less rating-scale infrastructure have failed because of placebo response rates of 30 to 45 percent, not because the active drug lacked pharmacology. Site monitoring and rater standardization across a 600-patient adaptive program is operationally demanding. Rating-scale drift (the tendency for clinician-administered scale scores to inflate over time as raters get less strict, which shrinks the apparent treatment effect because the placebo arm scores rise) is the specific failure mode that central rater training and adjudication are designed to prevent.

Our model estimates a 5% chance this drug is eventually approved. That estimate starts from the historical approval rate for Phase 2 drugs in this area, which is about 24%, then adjusts based on ten specific facts about the trial and sponsor. The number is helped by larger-than-typical enrollment, but pulled down by heavier-than-usual blinding, a thin or weak approval record from the sponsor, and weak or limited earlier-phase results. The remaining factors fall close to average for this stage, so they do not move the estimate much in either direction.

Efficacy risk dominates. MDD is the graveyard of psychiatric drug development because placebo response on MADRS commonly runs 30 to 45 percent and the patient population is biologically heterogeneous. Without a disclosed mechanism, there is no biomarker or clinical stratifier available to enrich for likely responders, which is the strategy modern MDD developers (zuranolone in postpartum depression, esketamine in treatment-resistant depression) have used to carve survivable signals out of the noise [3][4]. Safety risk is unquantifiable from public sources because no Phase 1 safety publication has been issued. CNS-active small molecules tend to surface hepatotoxicity, QT prolongation (the cardiac arrhythmia risk explained above), suicidality signals, and abuse-liability issues late, and the FDA's regulatory bar for novel-mechanism antidepressants now includes thorough QT studies (formal cardiac-safety studies designed to detect drug-induced QT prolongation at therapeutic and supratherapeutic exposures) and abuse-potential assessments that Sunshine Lake has not publicly addressed. Execution risk is meaningful at n=600 with adaptive transitions: tight site monitoring, rater training, and central MADRS adjudication are operationally expensive, and Sunshine Lake's published track record with multinational Phase 3 psychiatry trials is thin. Commercial risk runs in two channels. In the most likely near-term scenario, NMPA approval for the Chinese domestic market, the program faces competition from cheap generic SSRIs (escitalopram, sertraline, fluoxetine) priced at single-digit RMB per dose under volume-based procurement, plus a growing pipeline of domestic novel-mechanism entrants. Chinese MDD prevalence is high (lifetime estimates of major depressive disorder in mainland China commonly run in the tens of millions of adults), but realized pricing for branded antidepressants on the national reimbursement list is sharply lower than US or EU economics, so revenue per patient is a fraction of Western benchmarks. In the ex-China scenario, MDD is dominated by cheap generic SSRIs and SNRIs in the US and EU, and the differentiated entrants of the last decade have struggled to convert label approvals into the revenue investors initially modeled. A first-in-class molecule from a sponsor without an ex-China commercial presence would need a Western partner to reach US and EU patients at scale.

Watch but do not weight heavily. The single data point that would change the picture is external validation: a published mechanism-of-action paper, a Phase 1 safety publication in a Western journal, or an out-licensing deal to a developer with MDD infrastructure (Otsuka, Lundbeck, Sage, AbbVie, or Johnson & Johnson). Any of those would indicate the program has cleared an outside due-diligence bar, which is the missing piece today. The most probable near-term commercial outcome is a China-domestic NMPA filing roughly 12 to 24 months after the Phase 3 portion completes, given that the trial design is structured to support direct NMPA registration. That outcome is meaningful for HEC Pharm internally but a fraction of what an FDA approval would underwrite. HEC Pharm has produced Chinese approvals in antivirals and metabolic disease but has no marketed CNS asset outside China, so a successful international mitizodone program would be the group's first ex-China psychiatry play. HEC Pharm's specific consolidated revenue and R&D budget are not publicly disclosed (the group is privately held), so its ability to self-fund a global Phase 3 versus needing a Western partner is an open question and a key item for any BD team approaching the asset. The patent landscape for mitizodone is also underexposed in English-language indexes; CNIPA (China National Intellectual Property Administration) filings for the composition of matter almost certainly exist but have not been surfaced in indexed Western patent databases, and the absence of corresponding US or EP filings would itself be informative about Sunshine Lake's international ambitions. Check back when NCT04984512 posts a primary completion date update, when Sunshine Lake or HEC Pharm files a public mechanism disclosure, when a CNIPA or USPTO patent linked to mitizodone surfaces, or when the program appears at an international meeting such as ASCP, ECNP, or the CNS Summit [1]. The pre-computed PoS of 16.7 percent is a reasonable anchor; the 7.4 to 26.0 percent range reflects how much of the input is neutral defaults rather than verified evidence, and that uncertainty should shrink rapidly once mechanism and Phase 2 interim data become public.